Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03650114 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,882
- Enrollment target
- 20
- Study locations
NCT03650114 is a Phase 3 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 1,882 participants, below the 2,088-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT03650114, a Phase 3 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,882 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Ofatumumab
- BIOLOGICAL Tetanus toxoid (TT) containing vaccine (Td, Tdap)
- BIOLOGICAL 13-valent pneumococcal conjugate vaccine (13-PCV)
- BIOLOGICAL 23-valent pneumococcal polysaccharide vaccine (23-PPV)
- BIOLOGICAL Seasonal Quadrivalent influenza vaccine
Study Locations (20)
Florida
- Jem Research Institute - Atlantis
- Neurology Offices of South Florida PLLC - Delray Beach
- Infinity Clinical Research LLC - Hollywood
- Homestead Assoc In Research Inc - Homestead
- Neurology Associates PA - Maitland
- UM Department Of Neurology - Miami
- Aqualane Clinical Research - Naples
- MS and Neuromuscular Center of Excellence - Oldsmar
Colorado
- CU Anschutz Med Campus - Aurora
- Mountain Neuro Research Center PC - Basalt
- Alpine Clinical Research Center - Boulder
- Colorado Springs Neurological Associates - Colorado Springs
- Colorado Neurological Research PC - Denver
- University of Colorado Health Neurology - Fort Collins
Alabama
- University of Alabama at Birmingham - Birmingham
- North Central Neurology Associates PC - Cullman
California
- Fullerton Neuro and Headache Ctr - Fullerton
- University of California Davis - Sacramento
Arizona
- Barrow Neurological Clinics at St Josephs Hospital and MC - Phoenix
Delaware
- Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,882 participants |
| Start Date | 2018-12-28 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03650114
The ClinicalTrials.gov registry entry for NCT03650114 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,882 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,088-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (10% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 5 interventions - of which Ofatumumab is the first listed.
NCT03650114 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT03650114 about?
NCT03650114 is a clinical study titled "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS". The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab...
What is the current status of trial NCT03650114?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,882 participants. The study started on 2018-12-28. Estimated completion is 2028-09-30.
What conditions does trial NCT03650114 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT03650114?
The interventions under investigation include: Ofatumumab (BIOLOGICAL), Tetanus toxoid (TT) containing vaccine (Td, Tdap) (BIOLOGICAL), 13-valent pneumococcal conjugate vaccine (13-PCV) (BIOLOGICAL), 23-valent pneumococcal polysaccharide vaccine (23-PPV) (BIOLOGICAL), Seasonal Quadrivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03650114?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03650114 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.